{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T14:10:45Z","timestamp":1779286245520,"version":"3.51.4"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:00:00Z","timestamp":1667952000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:00:00Z","timestamp":1667952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012301","name":"Einstein-Mount Sinai Diabetes Research Center, Albert Einstein College of Medicine","doi-asserted-by":"publisher","award":["NIDDK P30DK020541-47"],"award-info":[{"award-number":["NIDDK P30DK020541-47"]}],"id":[{"id":"10.13039\/100012301","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Renin and angiotensin system inhibitors (RAASi) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) are recommended for patients with diabetic kidney disease (DKD) to reduce the progression to end-stage kidney disease; however, they are under-prescribed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To evaluate the frequency of care gaps in RAASi and SGLT2i prescription by patient demographic, health system, and clinical factors in patients with DKD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Design<\/jats:title>\n                <jats:p>Retrospective cohort study.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Participants<\/jats:title>\n                <jats:p>Adult primary care patients with DKD at an integrated health system in Bronx, NY, with 23 primary care sites in 2021.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Main Measures<\/jats:title>\n                <jats:p>The odds of having a care gap for (1) SGLT2i or (2) RAASi prescription. Multivariate logistic regression models were performed for each outcome measure to evaluate associations with patient demographic, health system, and clinical factors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Key Results<\/jats:title>\n                <jats:p>Of 7199 patients with DKD, 80.3% had a care gap in SGLT2i prescription and 42.0% had a care gap in RAASi prescription. For SGLT2i, patients with A1C at goal (aOR 2.32, 95% CI 1.96\u20132.73), Black non-Hispanic race\/ethnicity (aOR 1.46, 95% CI 1.15\u20131.87), and Hispanic race\/ethnicity (aOR 1.46, 95% CI 1.11\u20131.92) were more likely to experience a care gap. For RAASi, patients with blood pressure at goal (aOR 1.34, 95% CI 1.21\u20131.49) were more likely to experience a care gap.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The care gaps for SGLT2i and RAASi for patients with DKD with well-controlled diabetes and blood pressure suggest failure to recognize DKD as an independent indication for these medications. Racial\/ethnic disparities for SGLT2i, but not for RAASi, suggest systemic racism exacerbates care gaps for novel medications. These factors can be targets for interventions to improve patient care.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11606-022-07863-0","type":"journal-article","created":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T21:20:20Z","timestamp":1668028820000},"page":"1599-1605","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Care Gaps in Sodium-Glucose Cotransporter-2 Inhibitor and Renin Angiotensin System Inhibitor Prescriptions for Patients with Diabetic Kidney Disease"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2280-9033","authenticated-orcid":false,"given":"Sharon","family":"Rikin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Deccy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenshu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill","family":"Crandall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuting","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ladan","family":"Golestaneh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,9]]},"reference":[{"issue":"1 Suppl 1","key":"7863_CR1","doi-asserted-by":"publisher","first-page":"A6","DOI":"10.1053\/j.ajkd.2019.09.003","volume":"75","author":"R Saran","year":"2020","unstructured":"Saran R, Robinson B, Abbott KC, et al. US Renal Data System 2019 Annual Data Report: epidemiology of kidney disease in the United States. Am J Kidney Dis: the official journal of the National Kidney Foundation. 2020;75(1 Suppl 1):A6-a7.","journal-title":"Am J Kidney Dis: the official journal of the National Kidney Foundation."},{"key":"7863_CR2","unstructured":"Centers for Disease Control and Prevention. Chronic Kidney Disease Surveillance System\u2014United States. http:\/\/www.cdc.gov\/ckd. Accessed March 24, 2022."},{"issue":"7","key":"7863_CR3","doi-asserted-by":"publisher","first-page":"473","DOI":"10.7326\/M16-0273","volume":"165","author":"D Murphy","year":"2016","unstructured":"Murphy D, McCulloch CE, Lin F, et al. Trends in prevalence of chronic kidney disease in the United States. Ann Intern Med. 2016;165(7):473-481.","journal-title":"Ann Intern Med."},{"issue":"1","key":"7863_CR4","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2215\/CJN.07440618","volume":"14","author":"AR Chang","year":"2019","unstructured":"Chang AR, L\u00f3ser M, Malhotra R, Appel LJ. Blood pressure goals in patients with CKD: a review of evidence and guidelines. Clin J Am Soc Nephrol: CJASN. 2019;14(1):161-169.","journal-title":"Clin J Am Soc Nephrol: CJASN."},{"issue":"4","key":"7863_CR5","doi-asserted-by":"publisher","first-page":"244","DOI":"10.7326\/0003-4819-139-4-200308190-00006","volume":"139","author":"TH Jafar","year":"2003","unstructured":"Jafar TH, Stark PC, Schmid CH, et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med. 2003;139(4):244-252.","journal-title":"Ann Intern Med."},{"issue":"4","key":"7863_CR6","volume":"2006","author":"GF Strippoli","year":"2006","unstructured":"Strippoli GF, Bonifati C, Craig M, Navaneethan SD, Craig JC. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev. 2006;2006(4):Cd006257.","journal-title":"Cochrane Database Syst Rev."},{"issue":"11","key":"7863_CR7","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","volume":"7","author":"BL Neuen","year":"2019","unstructured":"Neuen BL, Young T, Heerspink HJL, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019;7(11):845-854.","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"24","key":"7863_CR8","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295-2306.","journal-title":"N Engl J Med."},{"issue":"15","key":"7863_CR9","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436-1446.","journal-title":"N Engl J Med."},{"issue":"22","key":"7863_CR10","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128.","journal-title":"N Engl J Med."},{"issue":"7","key":"7863_CR11","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644-657.","journal-title":"N Engl J Med."},{"issue":"12","key":"7863_CR12","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1089\/dia.2019.0213","volume":"21","author":"RG McCoy","year":"2019","unstructured":"McCoy RG, Dykhoff HJ, Sangaralingham L, et al. Adoption of new glucose-lowering medications in the U.S.\u2014the case of SGLT2 inhibitors: nationwide cohort study. Diabetes Technol Ther. 2019;21(12):702-712.","journal-title":"Diabetes Technol Ther."},{"issue":"3","key":"7863_CR13","doi-asserted-by":"publisher","first-page":"240","DOI":"10.2337\/cd19-0087","volume":"38","author":"IE McCoy","year":"2020","unstructured":"McCoy IE, Han J, Montez-Rath ME, Chertow GM, Rhee JJ. Patient and provider characteristics associated with sodium-glucose cotransporter 2 inhibitor prescription in patients with diabetes and proteinuric chronic kidney disease. Clinical Diabetes: a publication of the American Diabetes Association. 2020;38(3):240-247.","journal-title":"Clinical Diabetes: a publication of the American Diabetes Association."},{"issue":"4","key":"7863_CR14","doi-asserted-by":"publisher","first-page":"e216139","DOI":"10.1001\/jamanetworkopen.2021.6139","volume":"4","author":"LA Eberly","year":"2021","unstructured":"Eberly LA, Yang L, Eneanya ND, et al. Association of race\/ethnicity, gender, and socioeconomic status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US. JAMA Netw Open. 2021;4(4):e216139-e216139.","journal-title":"JAMA Netw Open."},{"issue":"6","key":"7863_CR15","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1053\/j.ajkd.2005.08.018","volume":"46","author":"WC Winkelmayer","year":"2005","unstructured":"Winkelmayer WC, Fischer MA, Schneeweiss S, Wang PS, Levin R, Avorn J. Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes. Am J Kidney Dis: the official journal of the National Kidney Foundation. 2005;46(6):1080-1087.","journal-title":"Am J Kidney Dis: the official journal of the National Kidney Foundation."},{"issue":"7","key":"7863_CR16","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1681\/ASN.2018100971","volume":"30","author":"DP Murphy","year":"2019","unstructured":"Murphy DP, Drawz PE, Foley RN. Trends in angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker use among those with impaired kidney function in the United States. J Am Soc Nephrol: JASN. 2019;30(7):1314-1321.","journal-title":"J Am Soc Nephrol: JASN."},{"issue":"12","key":"7863_CR17","first-page":"751","volume":"99","author":"K McGrath","year":"2019","unstructured":"McGrath K, Edi R. Diabetic kidney disease: diagnosis, treatment, and prevention. Am Fam Physician. 2019;99(12):751-759.","journal-title":"Am Fam Physician."},{"issue":"4, Supplement","key":"7863_CR18","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2020.06.019","volume":"98","author":"IH de Boer","year":"2020","unstructured":"de Boer IH, Caramori ML, Chan JCN, et al. KDIGO 2020 Clinical Practice Guideline for diabetes management in chronic kidney disease. Kidney Int. 2020;98(4, Supplement):S1-S115.","journal-title":"Kidney Int."},{"issue":"Supplement_1","key":"7863_CR19","doi-asserted-by":"publisher","first-page":"S125","DOI":"10.2337\/dc22-S009","volume":"45","author":"American Diabetes Association","year":"2021","unstructured":"American Diabetes Association. Chapter 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes\u20142022. Diabetes Care. 2021;45(Supplement_1):S125-S143.","journal-title":"Diabetes Care."},{"issue":"11 Suppl","key":"7863_CR20","first-page":"S212","volume":"21","author":"M Epstein","year":"2015","unstructured":"Epstein M, Reaven NL, Funk SE, McGaughey KJ, Oestreicher N, Knispel J. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. Am J Manag Care. 2015;21(11 Suppl):S212-220.","journal-title":"Am J Manag Care."},{"issue":"12","key":"7863_CR21","volume":"14","author":"V Sangha","year":"2021","unstructured":"Sangha V, Lipska K, Lin Z, et al. Patterns of prescribing sodium-glucose cotransporter-2 inhibitors for medicare beneficiaries in the United States. Circulation: Cardiovascular Quality and Outcomes. 2021;14(12):e008381.","journal-title":"Circulation: Cardiovascular Quality and Outcomes."},{"issue":"5","key":"7863_CR22","doi-asserted-by":"publisher","first-page":"e205411","DOI":"10.1001\/jamanetworkopen.2020.5411","volume":"3","author":"LG Gilstrap","year":"2020","unstructured":"Gilstrap LG, Blair RA, Huskamp HA, Zelevinsky K, Normand S-L. Assessment of second-generation diabetes medication initiation among Medicare enrollees from 2007 to 2015. JAMA Netw Open. 2020;3(5):e205411-e205411.","journal-title":"JAMA Netw Open."},{"issue":"25","key":"7863_CR23","doi-asserted-by":"publisher","first-page":"3370","DOI":"10.1016\/j.jacc.2018.08.2202","volume":"72","author":"M Vaduganathan","year":"2018","unstructured":"Vaduganathan M, Sathiyakumar V, Singh A, et al. Prescriber patterns of SGLT2i after expansions of U.S. Food and Drug Administration labeling. J Am Coll Cardiol. 2018;72(25):3370-3372.","journal-title":"J Am Coll Cardiol."},{"issue":"2","key":"7863_CR24","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1377\/hlthaff.2021.01394","volume":"41","author":"PA Braveman","year":"2022","unstructured":"Braveman PA, Arkin E, Proctor D, Kauh T, Holm N. Systemic and structural racism: definitions, examples, health damages, and approaches to dismantling. Health Affairs. 2022;41(2):171-178.","journal-title":"Health Affairs."},{"issue":"11","key":"7863_CR25","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1007\/s12325-018-0819-5","volume":"35","author":"J Okemah","year":"2018","unstructured":"Okemah J, Peng J, Qui\u00f1ones M. Addressing clinical inertia in type 2 diabetes mellitus: a review. Adv Ther. 2018;35(11):1735-1745.","journal-title":"Adv Ther."},{"issue":"1","key":"7863_CR26","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s12933-020-01154-w","volume":"19","author":"G Schernthaner","year":"2020","unstructured":"Schernthaner G, Shehadeh N, Ametov AS, et al. Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes. Cardiovasc Diabetol. 2020;19(1):185.","journal-title":"Cardiovasc Diabetol."},{"issue":"6","key":"7863_CR27","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.diabet.2017.06.003","volume":"43","author":"G Reach","year":"2017","unstructured":"Reach G, Pechtner V, Gentilella R, Corcos A, Ceriello A. Clinical inertia and its impact on treatment intensification in people with type 2 diabetes mellitus. Diabetes Metab. 2017;43(6):501-511.","journal-title":"Diabetes Metab."},{"issue":"2","key":"7863_CR28","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1111\/dom.13088","volume":"20","author":"K Khunti","year":"2018","unstructured":"Khunti K, Gomes MB, Pocock S, et al. Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: a systematic review. Diabetes Obes Metab. 2018;20(2):427-437.","journal-title":"Diabetes Obes Metab."},{"issue":"3","key":"7863_CR29","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/dme.12592","volume":"32","author":"A Zafar","year":"2015","unstructured":"Zafar A, Stone MA, Davies MJ, Khunti K. Acknowledging and allocating responsibility for clinical inertia in the management of type 2 diabetes in primary care: a qualitative study. Diabetic Med: a journal of the British Diabetic Association. 2015;32(3):407-413.","journal-title":"Diabetic Med: a journal of the British Diabetic Association."},{"issue":"4","key":"7863_CR30","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.jcjd.2021.12.005","volume":"46","author":"W Alkabbani","year":"2022","unstructured":"Alkabbani W, Zongo A, Minhas-Sandhu JK, et al. Sodium-glucose cotransporter-2 inhibitors and urinary tract infections: a propensity score-matched population-based cohort study. Can J Diabetes. 2022;46(4):392-403.e313.","journal-title":"Can J Diabetes."},{"issue":"4","key":"7863_CR31","doi-asserted-by":"publisher","first-page":"248","DOI":"10.7326\/M18-3136","volume":"171","author":"CV Dave","year":"2019","unstructured":"Dave CV, Schneeweiss S, Kim D, Fralick M, Tong A, Patorno E. Sodium\u2013glucose cotransporter-2 inhibitors and the risk for severe urinary tract infections. Ann Intern Med. 2019;171(4):248-256.","journal-title":"Ann Intern Med."},{"issue":"12","key":"7863_CR32","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1007\/s11606-008-0805-8","volume":"23","author":"ED Abbo","year":"2008","unstructured":"Abbo ED, Zhang Q, Zelder M, Huang ES. The increasing number of clinical items addressed during the time of adult primary care visits. J Gen Intern Med. 2008;23(12):2058-2065.","journal-title":"J Gen Intern Med."},{"issue":"11","key":"7863_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0110535","volume":"9","author":"LA Szczech","year":"2014","unstructured":"Szczech LA, Stewart RC, Su HL, et al. Primary care detection of chronic kidney disease in adults with type-2 diabetes: the ADD-CKD Study (awareness, detection and drug therapy in type 2 diabetes and chronic kidney disease). PLoS One. 2014;9(11):e110535.","journal-title":"PLoS One."},{"issue":"Suppl 1","key":"7863_CR34","doi-asserted-by":"publisher","first-page":"S90","DOI":"10.2337\/dc19-S009","volume":"42","author":"American Diabetes Association","year":"2019","unstructured":"American Diabetes Association. Chapter 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S90-s102.","journal-title":"Diabetes Care."},{"issue":"Supplement_1","key":"7863_CR35","doi-asserted-by":"publisher","first-page":"S98","DOI":"10.2337\/dc20-S009","volume":"43","author":"American Diabetes Association","year":"2019","unstructured":"American Diabetes Association. Chapter 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes\u20142020. Diabetes Care. 2019;43(Supplement_1):S98-S110.","journal-title":"Diabetes Care."},{"issue":"12","key":"7863_CR36","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1159\/000519758","volume":"52","author":"CJ Diamantidis","year":"2021","unstructured":"Diamantidis CJ, Zepel L, Wang V, et al. Disparities in chronic kidney disease progression by Medicare advantage enrollees. Am J Nephrol. 2021;52(12):949-957.","journal-title":"Am J Nephrol."},{"issue":"2","key":"7863_CR37","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1007\/s12020-021-02929-1","volume":"75","author":"S Madan","year":"2022","unstructured":"Madan S, Farooq M, Diab K, et al. Healthcare disparities in heart failure patients (with and without type 2 diabetes) and use of sodium glucose co-transport inhibitors (SGLT2-i). Endocrine. 2022;75(2):654-658.","journal-title":"Endocrine."},{"issue":"4","key":"7863_CR38","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1089\/dia.2020.0338","volume":"23","author":"S Agarwal","year":"2020","unstructured":"Agarwal S, Schechter C, Gonzalez J, Long JA. Racial\u2013ethnic disparities in diabetes technology use among young adults with type 1 diabetes. Diabetes Technol Ther. 2020;23(4):306-313.","journal-title":"Diabetes Technol Ther."},{"issue":"3","key":"7863_CR39","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1542\/peds.2014-1774","volume":"135","author":"SM Willi","year":"2015","unstructured":"Willi SM, Miller KM, DiMeglio LA, et al. Racial-ethnic disparities in management and outcomes among children with type 1 diabetes. Pediatrics. 2015;135(3):424-434.","journal-title":"Pediatrics."},{"issue":"1","key":"7863_CR40","doi-asserted-by":"publisher","first-page":"255","DOI":"10.2337\/dc20-1663","volume":"44","author":"CW Lai","year":"2021","unstructured":"Lai CW, Lipman TH, Willi SM, Hawkes CP. Racial and ethnic disparities in rates of continuous glucose monitor initiation and continued use in children with type 1 diabetes. Diabetes Care. 2021;44(1):255-257.","journal-title":"Diabetes Care."},{"issue":"1","key":"7863_CR41","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2337\/dc20-0257","volume":"44","author":"A Addala","year":"2021","unstructured":"Addala A, Auzanneau M, Miller K, et al. A decade of disparities in diabetes technology use and HbA(1c) in pediatric type 1 diabetes: a transatlantic comparison. Diabetes Care. 2021;44(1):133-140.","journal-title":"Diabetes Care."},{"issue":"4","key":"7863_CR42","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.119.005600","volume":"12","author":"AS Nathan","year":"2019","unstructured":"Nathan AS, Geng Z, Dayoub EJ, et al. Racial, ethnic, and socioeconomic inequities in the prescription of direct oral anticoagulants in patients with venous thromboembolism in the United States. Circ Cardiovasc Qual Outcomes. 2019;12(4):e005600.","journal-title":"Circ Cardiovasc Qual Outcomes."},{"issue":"12","key":"7863_CR43","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1001\/jamacardio.2018.3945","volume":"3","author":"UR Essien","year":"2018","unstructured":"Essien UR, Holmes DN, Jackson LR, 2nd, et al. Association of race\/ethnicity with oral anticoagulant use in patients with atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II. JAMA Cardiol. 2018;3(12):1174-1182.","journal-title":"JAMA Cardiol."},{"issue":"18","key":"7863_CR44","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1001\/jama.2021.17764","volume":"326","author":"UR Essien","year":"2021","unstructured":"Essien UR, Dusetzina SB, Gellad WF. A policy prescription for reducing health disparities-achieving pharmacoequity. JAMA. 2021;326(18):1793-1794.","journal-title":"JAMA."},{"issue":"2","key":"7863_CR45","doi-asserted-by":"publisher","first-page":"311","DOI":"10.2337\/dc08-1307","volume":"32","author":"ES Huang","year":"2009","unstructured":"Huang ES, Brown SES, Thakur N, et al. Racial\/ethnic differences in concerns about current and future medications among patients with type 2 diabetes. Diabetes Care. 2009;32(2):311-316.","journal-title":"Diabetes Care."},{"issue":"1","key":"7863_CR46","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s10880-020-09702-y","volume":"28","author":"M Pugh Jr","year":"2021","unstructured":"Pugh M, Jr., Perrin PB, Rybarczyk B, Tan J. Racism, mental health, healthcare provider trust, and medication adherence among Black patients in safety-net primary care. J Clin Psychol Med Settings. 2021;28(1):181-190.","journal-title":"J Clin Psychol Med Settings."},{"issue":"12","key":"7863_CR47","doi-asserted-by":"publisher","first-page":"e60","DOI":"10.2105\/AJPH.2015.302903","volume":"105","author":"WJ Hall","year":"2015","unstructured":"Hall WJ, Chapman MV, Lee KM, et al. Implicit racial\/ethnic bias among health care professionals and its influence on health care outcomes: a systematic review. Am J Public Health. 2015;105(12):e60-76.","journal-title":"Am J Public Health."},{"issue":"9","key":"7863_CR48","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1016\/j.pec.2019.04.023","volume":"102","author":"N Hagiwara","year":"2019","unstructured":"Hagiwara N, Elston Lafata J, Mezuk B, Vrana SR, Fetters MD. Detecting implicit racial bias in provider communication behaviors to reduce disparities in healthcare: challenges, solutions, and future directions for provider communication training. Patient Educ Couns. 2019;102(9):1738-1743.","journal-title":"Patient Educ Couns."},{"issue":"9","key":"7863_CR49","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1089\/dia.2021.0075","volume":"23","author":"S Agarwal","year":"2021","unstructured":"Agarwal S, Crespo-Ramos G, Long JA, Miller VA. \u201cI didn\u2019t really have a choice\u201d: qualitative analysis of racial-ethnic disparities in diabetes technology use among young adults with type 1 diabetes. Diabetes Technol Ther. 2021;23(9):616-622.","journal-title":"Diabetes Technol Ther."},{"key":"7863_CR50","doi-asserted-by":"crossref","first-page":"237437352211030","DOI":"10.1177\/23743735221103033","volume":"9","author":"SV Otte","year":"2022","unstructured":"Otte SV. Improved patient experience and outcomes: is patient-provider concordance the key? J Patient Exp. 2022;9:23743735221103033.","journal-title":"J Patient Exp."},{"issue":"11","key":"7863_CR51","doi-asserted-by":"publisher","first-page":"2902","DOI":"10.1097\/01.ASN.0000091586.46532.B4","volume":"14","author":"CY Hsu","year":"2003","unstructured":"Hsu CY, Lin F, Vittinghoff E, Shlipak MG. Racial differences in the progression from chronic renal insufficiency to end-stage renal disease in the United States. J Am Soc Nephrol: JASN. 2003;14(11):2902-2907.","journal-title":"J Am Soc Nephrol: JASN."}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-022-07863-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-022-07863-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-022-07863-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T15:11:46Z","timestamp":1685027506000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11606-022-07863-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,9]]},"references-count":51,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["7863"],"URL":"https:\/\/doi.org\/10.1007\/s11606-022-07863-0","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,9]]},"assertion":[{"value":"27 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Golestaneh reports support for attending meeting of the National Kidney Foundation. Dr. Crandall reports continuous glucose monitors provided for use in a research study from Abbott. The other authors have no disclosures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}